We don't work in isolation – never have, never will. We partner with dozens of scientific
collaborators to advance our mission to end ALS. We also enter into strategic funding
alliances with foundations and nonprofits from across the spectrum of neurodegeneration.
Using proprietary genomic and proteomic data collected by TDI and leveraged against
the published literature, we have identified several highly relevant disease associated
molecular targets. Our current pipeline contains 30 programs targeting these various
aspects of neurodegenerative disease pathology. Our team of 30 industry-trained
scientists is advancing these projects through the preclinical pipeline at our state-of-the-art,
15,000 square-foot research center in Cambridge's Kendall Square. We are currently
seeking partners interested in making strategic investments in projects currently
in our pipeline or translating late-stage projects from ALS TDI toward the clinic.
TDI develops appropriate intellectual property protection on several molecules each
year following the development of supporting data. Each of these molecules represents
a potentially important and lucrative opportunity for patients and corporations
We have developed a continuum of partnership models to support the advancement and
translation of potentially life changing therapeutics into the clinic and ultimately
the marketplace. As the world's leading preclinical research center for ALS, we
work with pharmaceutical and biotechnology organizations, academic leaders, and
start-ups. In 2011, TDI had six contract research agreements with the largest global
drug development companies and 12 collaborations with universities and other corporations.
Our partners receive world-class support and access to our research team and infrastructure.
We are eager to work with others that share our mission to reduce the time and cost
it takes to develop life saving medicine for patients today.
If you would like to explore a potential collaboration with ALS TDI or if you are
a representative of a university or company interested in ALS learning more about
our current pipeline, please contact our Business Development and Venture Team.
“Our relationship with ALS TDI is producing tangible results for the worldwide ALS
community. This fast-track effort is altering the way researchers advance potential
treatments for ALS and has helped many labs evaluate candidate therapeutics quicker
and more efficiently than before,” said R. Rodney Howell, M.D., Chairman of the
MDA Board of Directors.
The Muscular Dystrophy Association (MDA) announced on March 3, 2011 that it has
extended its research partnership with the ALS Therapy Development Institute (ALS
TDI) through its flagship ALS fundraising initiative, Augie's Quest. Augie's Quest
is led by its Chief Inspiration Officer, Augie Nieto, a well known fitness pioneer
diagnosed in 2005 with ALS. Nieto has raised and invested $22 million since 2007
into ALS TDI. This crucial funding has led to a number of potential therapeutics
being identified and developed by ALS TDI, including its lead candidate known as
ALS TDI 00846.
“ALS TDI has already made an important contribution in advancing the science of preclinical
animal trials for new drugs for neurodegenerative disease,” said Howard Fillit,
M.D., executive director of the Alzheimer's Drug Discovery Foundation.
On March 22, 2011 the Alzheimer's Drug Discovery Foundation (ADDF), the Association
for Frontotemporal Degeneration (AFTD) and the MDA announced that they were collaborating
with ALS TDI to jointly fund the characterization of a new model of neurodegeneration
called the TDP-43 mouse. TDP-43 mutations have been associated with many neurodegenerative
disorders. Each partner supplied significant funding to the nine month and $1 million
“By bringing together the Aestus technology for accelerated identification of potential
drugs, and ALS TDI's vast knowledge and experience with ALS disease models and clinical
drug development, we look forward to the rapid and efficient discovery of novel,
effective therapies against this complex and devastating disease,” said Tage Honore,
Ph.D., DSc., CEO & co-founder of Aestus.
Aestus Therapeutics, Inc., has a multi-year collaboration to test several potential
small-molecule compounds to slow or stop the progression of ALS. An innovative translational
medicine company, Aestus has used their complex, proprietary biological data mining
techniques to identify therapeutics for screening against targets associated with
ALS disease onset or progression. All screening will be conducted at ALS TDI.